Page last updated: 2024-11-02

oxybutynin and Heart Valve Diseases

oxybutynin has been researched along with Heart Valve Diseases in 1 studies

oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.

Heart Valve Diseases: Pathological conditions involving any of the various HEART VALVES and the associated structures (PAPILLARY MUSCLES and CHORDAE TENDINEAE).

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Müller, T	1
Tolosa, E	1
Badea, L	1
Asgharnejad, M	1
Grieger, F	1
Markowitz, M	1
Nondonfaz, X	1
Bauer, L	1
Timmermann, L	1

Clinical Trials (1)

Trial Overview

Trial			Phase	Enrollment	Study Type	Start Date	Status
A Naturalistic, Multisite, Observational Study of Rotigotine Transdermal Patch and Other Currently Prescribed Therapies in Patients With Idiopathic Parkinson's Disease[NCT00599339]				2,195 participants (Actual)	Observational	2006-06-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in Nocturnal Dystonia Cramp Score (NADCS) at Visit 7 (Month 33)

"The NADCS assesses sleep-related motor complaints including nocturnal akinesia, dystonia and painful cramps by an ordinal severity scale.~The NADCS total score ranges from 0 (normal) to 4 (maximum severity). NADCS value was missing for one subject at Visit 7." (NCT00599339)
Timeframe: 33 months

Intervention	units on a scale (Mean)
Neupro Monotherapy (>= 3 Months)	-0.27
Neupro Monotherapy (< 3 Months)	1.36
Other Dopamine Agonist (>= 3 Months)	-0.15
Other Dopamine Agonist (< 3 Months)	0.05
L-Dopa Monotherapy (>= 3 Months)	-0.09
L-Dopa Monotherapy (< 3 Months)	-0.26
Multiple Dopamine Agonists (>= 3 Months)	-0.73
Multiple Dopamine Agonists (< 3 Months)	0.75
Neupro + L-Dopa (>= 3 Months)	-0.03
Neupro + L-Dopa (< 3 Months)	-0.42
Other Dopamine Agonist + L-Dopa (>= 3 Months)	-0.03
Other Dopamine Agonist + L-Dopa (< 3 Months)	1.05
Multiple Dopamine Agonists + L-Dopa (>= 3 Months)	-0.01
Multiple Dopamine Agonists + L-Dopa (< 3 Months)	3.25
Not Treated (>= 3 Months)	-0.38
Not Treated (< 3 Months)	0.22

Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part III at Visit 7 (Month 33)

The Unified Parkinson's disease rating scale (UPDRS) Part III (Motor Examination) contains 31 questions. Each question ranges from 0 (best possible outcome) to 4 (worst outcome). The total score ranges from 0 (best possible outcome) to 124 (worst outcome). (NCT00599339)
Timeframe: From Baseline to Visit 7 (Month 33)

Intervention	units on a scale (Mean)
Neupro Monotherapy (>= 3 Months)	-2.5
Neupro Monotherapy (< 3 Months)	-2.5
Other Dopamine Agonist (>= 3 Months)	-2.2
Other Dopamine Agonist (< 3 Months)	-5.6
L-Dopa Monotherapy (>= 3 Months)	0.2
L-Dopa Monotherapy (< 3 Months)	0.0
Multiple Dopamine Agonists (>= 3 Months)	-1.2
Multiple Dopamine Agonists (< 3 Months)	3.5
Neupro + L-Dopa (>= 3 Months)	-1.2
Neupro + L-Dopa (< 3 Months)	-1.5
Other Dopamine Agonist + L-Dopa (>= 3 Months)	-2.5
Other Dopamine Agonist + L-Dopa (< 3 Months)	8.6
Multiple Dopamine Agonists + L-Dopa (>= 3 Months)	1.5
Multiple Dopamine Agonists + L-Dopa (< 3 Months)	20.0
Not Treated (>= 3 Months)	-3.2
Not Treated (< 3 Months)	4.1

Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Question 32 of Part IV at Visit 7 (Month 33)

"The Unified Parkinson's disease rating scale (UPDRS) question 32 of part IV asks. What Proportion of the waking day are dyskinesias present? Answers range from 0 (None) to 4 (76-100 % of the day)." (NCT00599339)
Timeframe: From Baseline to Visit 7 (Month 33)

Intervention	units on a scale (Mean)
Neupro Monotherapy (>= 3 Months)	-0.1
Neupro Monotherapy (< 3 Months)	-0.2
Other Dopamine Agonist (>= 3 Months)	-0.1
Other Dopamine Agonist (< 3 Months)	0.0
L-Dopa Monotherapy (>= 3 Months)	0.1
L-Dopa Monotherapy (< 3 Months)	-0.1
Multiple Dopamine Agonists (>= 3 Months)	-0.1
Multiple Dopamine Agonists (< 3 Months)	0.0
Neupro + L-Dopa (>= 3 Months)	0.1
Neupro + L-Dopa (< 3 Months)	0.2
Other Dopamine Agonist + L-Dopa (>= 3 Months)	0.2
Other Dopamine Agonist + L-Dopa (< 3 Months)	0.2
Multiple Dopamine Agonists + L-Dopa (>= 3 Months)	0.2
Multiple Dopamine Agonists + L-Dopa (< 3 Months)	0.5
Not Treated (>= 3 Months)	-0.2
Not Treated (< 3 Months)	0.1

Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Question 33 of Part IV at Visit 7 (Month 33)

"The Unified Parkinson's disease rating scale (UPDRS) Part IV question 33 asks for complications of therapy in the past week, through the question How disabling are the dyskinesias ? Answers range from 0 (Not disabling) to 4 (Completely disabling)." (NCT00599339)
Timeframe: From Baseline to Visit 7 (Month 33)

Intervention	units on a scale (Mean)
Neupro Monotherapy (>= 3 Months)	-0.1
Neupro Monotherapy (< 3 Months)	-0.2
Other Dopamine Agonist (>= 3 Months)	-0.1
Other Dopamine Agonist (< 3 Months)	-0.1
L-Dopa Monotherapy (>= 3 Months)	0.0
L-Dopa Monotherapy (< 3 Months)	-0.0
Multiple Dopamine Agonists (>= 3 Months)	-0.1
Multiple Dopamine Agonists (< 3 Months)	0.0
Neupro + L-Dopa (>= 3 Months)	0.0
Neupro + L-Dopa (< 3 Months)	0.0
Other Dopamine Agonist + L-Dopa (>= 3 Months)	0.1
Other Dopamine Agonist + L-Dopa (< 3 Months)	-0.1
Multiple Dopamine Agonists + L-Dopa (>= 3 Months)	0.2
Multiple Dopamine Agonists + L-Dopa (< 3 Months)	0.0
Not Treated (>= 3 Months)	-0.1
Not Treated (< 3 Months)	0.2

Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Question 39 of Part IV at Visit 7 (Month 33)

"The Unified Parkinson's disease rating scale (UPDRS) Part IV question 39 asks What proportion of the waking day is the patient off, on average? Answers range from 0 (None) to 4 (76-100 % of the day)." (NCT00599339)
Timeframe: 33 months

Intervention	units on a scale (Mean)
Neupro Monotherapy (>= 3 Months)	-0.2
Neupro Monotherapy (< 3 Months)	0.5
Other Dopamine Agonist (>= 3 Months)	-0.1
Other Dopamine Agonist (< 3 Months)	0.1
L-Dopa Monotherapy (>= 3 Months)	0.1
L-Dopa Monotherapy (< 3 Months)	0.1
Multiple Dopamine Agonists (>= 3 Months)	-0.4
Multiple Dopamine Agonists (< 3 Months)	0.0
Neupro + L-Dopa (>= 3 Months)	0.0
Neupro + L-Dopa (< 3 Months)	0.0
Other Dopamine Agonist + L-Dopa (>= 3 Months)	0.2
Other Dopamine Agonist + L-Dopa (< 3 Months)	0.2
Multiple Dopamine Agonists + L-Dopa (>= 3 Months)	-0.0
Multiple Dopamine Agonists + L-Dopa (< 3 Months)	1.5
Not Treated (>= 3 Months)	0.0
Not Treated (< 3 Months)	0.3

Hoehn & Yahr Stage at Visit 7 (Month 33)

"The Hoehn and Yahr staging of Parkinson's disease in the on stage, if applicable, had to be completed by the physician.~Possible staging:~0 No signs of disease~1 Unilateral disease~2 Bilateral disease without impairment of balance~3 Mild to moderate bilateral disease, some postural instability, physically dependent~4 Severe disability, still able to walk or stand unassisted~5 Wheelchair bound or bedridden unless aided" (NCT00599339)
Timeframe: 33 months

,,,,,,,,,,,,,,,

Intervention	participants (Number)
	0	1	2	3	4	5	No Data/Missing
L-Dopa Monotherapy (< 3 Months)	0	1	12	8	2	0	0
L-Dopa Monotherapy (>= 3 Months)	0	29	118	70	14	3	0
Multiple Dopamine Agonists (< 3 Months)	0	1	1	0	0	0	0
Multiple Dopamine Agonists (>= 3 Months)	0	0	7	5	1	0	0
Multiple Dopamine Agonists + L-Dopa (< 3 Months)	0	0	1	0	1	0	0
Multiple Dopamine Agonists + L-Dopa (>= 3 Months)	0	2	15	13	3	2	1
Neupro + L-Dopa (< 3 Months)	0	2	2	2	0	0	0
Neupro + L-Dopa (>= 3 Months)	2	29	186	131	46	6	1
Neupro Monotherapy (< 3 Months)	0	1	4	4	2	0	0
Neupro Monotherapy (>= 3 Months)	2	55	112	28	8	1	1
Not Treated (< 3 Months)	0	3	19	11	3	1	0
Not Treated (>= 3 Months)	0	4	7	1	1	0	0
Other Dopamine Agonist (< 3 Months)	0	0	6	4	0	0	1
Other Dopamine Agonist (>= 3 Months)	0	48	76	19	2	0	1
Other Dopamine Agonist + L-Dopa (< 3 Months)	0	0	2	4	4	1	0
Other Dopamine Agonist + L-Dopa (>= 3 Months)	1	37	192	119	24	4	1

Reported Adverse Events of Cardiac Valve Fibrosis During the Study (up to 33 Months)

The analysis was performed for the non-disjunctive classification into patients at risk to develop an Adverse Event associated with Rotigotine and patients at risk to develop an Adverse Event not associated with Rotigotine. (NCT00599339)
Timeframe: 33 months

Intervention	Adverse Events (Number)
	Cardiac valve disease	Cardiac valve sclerosis	Aortic valve sclerosis
Associated With Rotigotine	1	0	1
Not Associated With Rotigotine	1	2	0

Other Studies

1 other study available for oxybutynin and Heart Valve Diseases

Article	Year
An observational study of rotigotine transdermal patch and other currently prescribed therapies in patients with Parkinson's disease. Journal of neural transmission (Vienna, Austria : 1996), 2018, Volume: 125, Issue:6 Topics: Aged; Antiparkinson Agents; Dopamine Agonists; Drug Therapy, Combination; Female; Heart Valve Diseas	2018